Skip to content
OpenCapital
Get started

Vaxcyte, Inc. PCVX Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One

Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One at other companies

Moderna logo
ModernaMRNA
——

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0×0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one?
Vaxcyte, Inc. (PCVX) reported debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one of $1.48B in Q1 2026.
How has Vaxcyte, Inc.'s debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one changed year-over-year?
Vaxcyte, Inc.'s debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, year one increased by 11.4% year-over-year, from $1.32B to $1.48B.